Oncology Revenue | | | | | | | | | | | |
Oncology Revenue % Chg. | | | | | | | | | | | |
BioPharmaceuticals: CVRM Revenue | | | | | | | | | | | |
BioPharmaceuticals: CVRM Revenue % Chg. | | | | | | | | | | | |
BioPharmaceuticals: R&I Revenue | | | | | | | | | | | |
BioPharmaceuticals: R&I Revenue % Chg. | | | | | | | | | | | |
BioPharmaceuticals V&I Revenue | | | | | | | | | | | |
Rare Disease Revenue | | | | | | | | | | | |
Rare Disease Revenue % Chg. | | | | | | | | | | | |
Other Medicines Revenue | | | | | | | | | | | |
Other Medicines Revenue % Chg. | | | | | | | | | | | |
COVID-19 Revenue | | | | | | | | | | | |
COVID-19 Revenue % Chg. | | | | | | | | | | | |
Collaboration Revenue | | | | | | | | | | | |
UK Revenue | | | | | | | | | | | |
UK Revenue % Chg. | | | | | | | | | | | |
Rest of Europe Revenue | | | | | | | | | | | |
Rest of Europe Revenue % Chg. | | | | | | | | | | | |
The Americas Revenue | | | | | | | | | | | |
The Americas Revenue % Chg. | | | | | | | | | | | |
Asia, Africa & Australasia Revenue | | | | | | | | | | | |
Asia, Africa & Australasia Revenue % Chg. | | | | | | | | | | | |
UK Operating Profit | | | | | | | | | | | |
UK Operating Profit % Chg. | | | | | | | | | | | |
Rest of Europe Operating Profit | | | | | | | | | | | |
Rest of Europe Operating Profit % Chg. | | | | | | | | | | | |
The Americas Operating Profit | | | | | | | | | | | |
The Americas Operating Profit % Chg. | | | | | | | | | | | |
Asia, Africa & Australasia Operating Profit | | | | | | | | | | | |
Asia, Africa & Australasia Operating Profit % Chg. | | | | | | | | | | | |
UK Assets Acquired | | | | | | | | | | | |
UK Assets Acquired % Chg. | | | | | | | | | | | |
Rest of Europe Assets Acquired | | | | | | | | | | | |
Rest of Europe Assets Acquired % Chg. | | | | | | | | | | | |
The Americas Assets Acquired | | | | | | | | | | | |
The Americas Assets Acquired % Chg. | | | | | | | | | | | |
Asia, Africa & Australasia Assets Acquired | | | | | | | | | | | |
Asia, Africa & Australasia Assets Acquired % Chg. | | | | | | | | | | | |